The impact of reducing cardiovascular medication copayments on health spending and resource utilization

Area of Science:

• Health economics
• Cardiovascular pharmacoeconomics
• Public health policy

Background:

• Patient cost-sharing, or copayments, is a common strategy to control healthcare expenditures.
• While reduced copayments for secondary cardiovascular prevention post-myocardial infarction are known to be beneficial, their impact on lower-risk populations and other essential medications remains under-researched.
• This study addresses the gap by examining the effects of copayment reductions for statins and clopidogrel in a broader patient cohort.

Purpose of the Study:

• To assess the influence of decreased copayments for statin and clopidogrel medications on cardiovascular resource utilization.
• To evaluate the impact of these copayment reductions on the occurrence of major coronary events.
• To determine the effect on overall insurer spending and patient out-of-pocket expenses.

Main Methods:

• A quasi-experimental design was employed, comparing a self-insured employer that implemented copayment reductions with control companies.
• The intervention group included patients with diabetes or vascular disease receiving reduced statin copayments and all patients prescribed clopidogrel with reduced copayments (n = 3,513).
• A control group of 49,803 individuals from companies without the policy was used for comparison, with analyses conducted using segmented regression models and generalized estimating equations.

Main Results:

• Lower copayments correlated with significant decreases in physician visits and hospitalizations/emergency department admissions for both statin and clopidogrel users.
• No significant impact was observed on the incidence of major coronary events.
• Patient out-of-pocket spending for medications and other services decreased substantially, while overall health spending remained cost-neutral.

Conclusions:

• Implementing reduced copayments for statins and clopidogrel effectively decreased healthcare resource utilization and patient financial burden.
• The policy demonstrated cost neutrality concerning total healthcare expenditures, suggesting a viable strategy for managing cardiovascular medication access.
• Findings support the potential for copayment reduction as a cost-effective approach to enhance adherence and reduce resource use in cardiovascular care.